Does low-dose naltrexone help chronic pain, fatigue or autoimmune symptoms, and how is it different from standard-dose naltrexone?

Naltrexone blocks opioid receptors and is used at standard doses in treatment for alcohol and opioid use disorders. “Low-dose naltrexone” refers to substantially smaller amounts prescribed off-label for conditions such as fibromyalgia. Proposed effects on pain signaling and immune cells are research hypotheses, not proof that it broadly resets the immune system. Early small studies generated interest, but a 2024 randomized trial in 99 women with fibromyalgia did not show superiority over placebo for pain relief. The 2026 INNOVA trial also failed to establish a clear pain advantage.[1][2][3]

That does not prove no individual can benefit, but it makes confident claims about treating chronic fatigue or autoimmune disease premature. Each condition needs its own controlled trials, and symptom improvement should be separated from control of the underlying disease. Low dose also does not erase the drug’s opioid-blocking action: it can interfere with opioid pain medicines and precipitate withdrawal in someone who is opioid-dependent. A prescribing clinician needs to review opioid exposure and the treatment goal. It should not be treated as an interchangeable substitute for established disease-modifying treatment.[1][2][3]